Braeburn Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRAEBURN, and when can generic versions of BRAEBURN drugs launch?
BRAEBURN has one approved drug.
There are seven US patents protecting BRAEBURN drugs.
There are one hundred patent family members on BRAEBURN drugs in thirty-three countries.
Summary for Braeburn
| International Patents: | 100 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Braeburn
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-003 | May 23, 2023 | RX | Yes | No | 9,937,164 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-004 | May 23, 2023 | RX | Yes | No | 8,545,832 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Braeburn | BRIXADI | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 210136-002 | May 23, 2023 | RX | Yes | No | 8,545,832 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Braeburn Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 6417327 | ⤷ Subscribe |
| New Zealand | 735248 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2006131730 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
